• 1
    Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol Oncol Clin North Am. 1995; 9: 765785.
  • 2
    Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993; 11: 12691275.
  • 3
    Edmonson JH. Needed: qualitative improvement in antisarcoma therapy. J Clin Oncol. 1995; 13: 15311533.
  • 4
    Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995; 22 (11): 310.
  • 5
    Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G, Peters GJ. Schedule-dependent antitumor effect of gemcitabine in in vivo model systems. Semin Oncol. 1995; 22 (11): 4246.
  • 6
    Merimsky O, Meller I, Flusser G, et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol. 2000; 45 (2): 177181.
  • 7
    Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10: 110.
  • 8
    Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 9
    Le Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma group. J Clin Oncol. 2000; 18 (14): 26762684.
  • 10
    Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993; 11 (7): 12761285.
  • 11
    Patel, SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001; 19 (15): 34833489.
  • 12
    Okuno SH, Edmonson JH, Mahoney MR, et al. Limited activity and acceptable toxicity of gemcitabine in a phase 2 study of patients with advanced sarcomas: a Mayo Cancer Center Study [abstract 2188]. Proc Am Soc Clin Oncol. 2000; 19: 555a.
  • 13
    Hensley ML, Venkatraman E, Maki R, et al. Docetaxel (D) plus gemcitabine (G) is active in leiomyosarcoma (LMS): results of a phase II trial [abstract 1408]. Proc Am Soc Clin Oncol. 2001; 20: 353a.
  • 14
    Spath-Schwalbe E, Genvresse I, Koschuth A, Dietzmann A, Grunewald R, Possinger K. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs. 2000; 11: 325329.
  • 15
    Brambilla L, Labianca R, Ferrucci SM, Taglioni M, Boneschi V. Treatment of classical Kaposi's sarcoma with gemcitabine. Dermatology. 2001; 202: 119122.
  • 16
    Van Glabbeke M, Van Oosterom AT, Oosterhuis JW, et al. Prognostic factors in advanced soft tissue sarcoma (STS): an overview of 1742 patients treated with docorubicin containing first line regimens by the EORTC Soft Tissue and Bone Sarcoma group (STBSG). Ann Oncol. 1994; 2 (Suppl 8): 171.
  • 17
    Blanke CD, von Mehren M, Joensuu H, et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571 in patients (Pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing C-KIT (CD117). Proc Am Soc Clin Oncol. 2001; 20: 1a(abstr. 1).
  • 18
    Van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI 571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet. 2001; 358: 14211423.